Nesiritide is a recombinant formulation of brain-type natriuretic factor. Preliminary experience in the adult population suggests that nesiritide may be an effective agent in the treatment of decompensated congestive heart failure. Given its physiologic effects, it may be an effective agent in the pediatric population; however, to date, there are no reports regarding its use in infants and children. The authors retrospectively review their experience with nesiritide in 5 pediatric patients. The cohort of 5 patients included a diverse population with 2 patients who were status postcardiothoracic surgery, 2 with adult respiratory distress syndrome, and 1 in the recovery phase from septic shock. Although no direct measurement of cardiac output was feasible as none of the patients had a pulmonary artery catheter, other indicators of increased cardiac output were noted. These included improved peripheral perfusion with warming of the extremities and improvement of peripheral pulses in all of the patients, increased venous saturation in 2 of the patients, and maintenance of or increased urine output despite weaning or discontinuation of diuretics. In 3 of the patients, nesiritide was started as the primary agent to provide a decrease in systemic vascular resistance and augment cardiac output, while in the other 2 patients, nesiritide was used when other vasoactive agents failed to provide the desired effect or resulted in adverse effects.
Nesiritide (Natrecor, Scios, Sunnyvale, Calif) is a recombinant formulation of B-type natriuretic peptide (BNP). Although originally isolated from porcine brain, the highest concentration of BNP is actually in the heart, and it has subsequently been shown to play a key role in the regulation of intravascular volume and vascular tone. Endogenous BNP is produced by ventricular myocytes in response to ventricular wall stretch that may occur with ventricular stress, hypertrophy, or volume overload. Recombinant BNP is composed of a 32-amino acid sequence that is identical to endogenous BNP. The physiologic effects of BNP include natriuresis, diuresis, and smooth muscle relaxation. These physiologic effects lead to the therapeutic benefits of venous, arterial, and coronary vasodilation and decreases in preload and afterload, resulting in increased cardiac output with improved peripheral perfusion [1] [2] [3] . Nesiritide is used most commonly in the treatment of adults with New York Heart Association class IV congestive heart failure (CHF) with dyspnea at rest or signs of volume overload [1] [2] [3] . Given its physiologic effects, it may be useful in other clinical scenarios. To date, there are no reports regarding the use of this agent in the pediatric population. We present our initial experience with the use of nesiritide in 5 infants and children. Previous reports regarding its use in adults are reviewed, and suggestions are presented regarding its potential applications in infants and children.
Case Reports
The retrospective review of the patients' charts and reporting of their clinical course was approved by the Institutional Review Board of the University of Missouri.
Patient 1
A 3-year-old, 15-kg boy was ejected from a car after a motor vehicle accident. His trachea was intubated at the scene, and on arrival to the emergency room, bilateral thoracostomy tubes were placed for tension pneumothoraces. The remainder of the trauma evaluation was negative except for a right temporal bone fracture and cerebrospinal fluid otorrhea. Fluid resuscitation was started for hypotension, and blood pressure support with dopamine and epinephrine was necessary. Oxygenation and ventilation became progressively more difficult over the first hour after arrival to the emergency room, and following admission to the pediatric intensive care unit (PICU), high-frequency oscillatory ventilation (HFOV) and nitric oxide were initiated. Neuromuscular blockade was provided by a continuous infusion of cis-atracurium, sedation by a continuous infusion of midazolam, and analgesia with intermittent doses of morphine. Dopamine and epinephrine were titrated to maintain an adequate mean arterial pressure. Over the first 36 hours of hospitalization, the patient's blood pressure stabilized, and he was weaned from dopamine and then the epinephrine, which were then discontinued. However, the patient's respiratory status remained tenuous with HFOV at a mean airway pressure of 30 to 32 mmHg and nitric oxide at 40 parts per million necessary to maintain oxygenation. Forty-eight hours after admission, the patient's blood pressure increased to 120-130/70-80 mmHg. The mixed venous oxygen saturation measured from the central line at the superior vena cava/right atrial junction was 54%. Urine output had decreased to an average of 0.5 mL/kg/h for the past 6 hours. Central venous pressure (CVP) was 17 mmHg. There was an increase in the urine output following a dose of furosemide and again following a dose of mannitol; however, there was decreased peripheral perfusion with cool extremities. Nesiritide was started at 0.01 mcg/kg/min. Fluid balance for the next 16 hours was an input of 1777 mL and an output of 749 mL (3.1 ml/kg/h). The blood pressure decreased to 110-120/60-70 mmHg. Nesiritide was increased to 0.02 mcg/kg/min. Mixed venous oxygen saturation was 64%, and the patient's hands and feet were warm. For the next 3 days, the cumulative net fluid output over the fluid input was 1362 mL, 315 mL, and 485 mL, respectively. The blood pressure stabilized at 80-100/40-60 mmHg, and the CVP decreased to 10-12 mmHg. Nesiritide was continued for a total of 6 days. During this time, the patient's ventilatory support was decreased and switched over to conventional positive-pressure ventilation. At that time, nesiritide was discontinued. The remainder of the patient's hospital course was uneventful, and he was discharged home without residual deficit.
Patient 2
An 8-year-old, 25-kg boy was admitted to the PICU after a closed head injury and evacuation of an epidural hematoma. Intraoperatively, increased mean airway pressures were noted and a postoperative chest x-ray revealed bilateral alveolar infiltrates suggestive of neurogenic pulmonary edema. Because of an inability to oxygenate with conventional ventilation, HFOV was instituted. The patient had 2 to 3 episodes of severe hypotension and was resuscitated with fluid and inotropic agents including infusions of epinephrine and dopamine. Over the next 48 hours, the patient's cardiorespiratory status stabilized, and the epinephrine was discontinued. Dopamine was continued at 12 mcg/kg/min for support of blood pressure, resulting in a systolic blood pressure of 90-100 mmHg. Physical examination revealed cool extremities from the knees and elbows down. Over a 24-hour period, the fluid input was 3670 mL with 1900 mL of urine output (3.2 mL/kg/h). Urine output was maintained with intermittent doses of furosemide. Nesiritide was started at 0.01 mcg/kg/min, and 5 to 6 hours later, it was increased to 0.02 mcg/kg/min since the hands and feet were still cool although the arms and legs were warm. During the first 24 hours following nesiritide initiation, the cumulative fluid was 3335, with a urine output of 2700 mL (4.5 mL/kg/h). One dose of diuretic (furosemide) was administered during this time. The CVP was 14 to 15 mmHg prior to starting nesiritide and decreased to 11 to 12 mmHg. During this time, there was improvement in the peripheral perfusion with warming of the hands and feet. At 36 hours, the nesiritide was increased to 0.03 mcg/kg/min in an attempt to further increase the urine output. Urine output remained at 4 to 4.5 mL/kg/h. Nesiritide was continued for a total of 5 days. A gradual decrease in the serum sodium was noted during the nesiritide administration with a urine sodium of 100 mEq/L. Sodium supplementation resulted in a correction of the sodium to the normal range. A diagnosis of cerebral salt wasting was made. Supplemental sodium administration was necessary, and the increased urine sodium concentration persisted after discontinuation of the nesiritide infusion.
Patient 3
A 3-month-old, 3.2-kg infant was admitted to the PICU following repair of aortic coarctation. Following the procedure, his trachea was extubat- ed. Analgesia was provided by intermittent doses of nalbuphine (0.1 mg/kg every 2 hours as needed) and rectal acetaminophen. Postoperative echocardiography revealed minimal residual gradient across the repair site and normal ventricular function. Approximately 20 hours postoperatively, the patient developed hypertension with blood pressures of 110-120/70-80 mmHg in both the upper and lower extremities. The CVP was 7 to 9 mmHg. Urine output during this time was 1.3 mL/kg/h. Nesiritide was started at 0.01 mcg/kg/min. This resulted in a decrease in the blood pressure to 90-95/55-60 mmHg. Two hours later, to achieve better blood pressure control, the nesiritide was increased to 0.02 mcg/kg/min. After this, the blood pressure decreased to 70-90/40-50 mmHg. No change was noted in the CVP. Urine output during nesiritide therapy was 2.6 mL/kg/h. The patient had 1 episode of hypertension (122/88 mmHg) during agitation on postoperative day 2, which was treated with nalbuphine for pain control. Nesiritide was continued for approximately 60 hours, and the patient was transitioned to oral enalapril for chronic blood pressure therapy. With the initiation of enalapril therapy and discontinuation of the nesiritide, there was a transient increase in the blood pressure back to the levels seen prior to the nesiritide infusion. Effective blood pressure control was eventually achieved with increasing the enalapril dose and frequency. The remainder of the patient's hospital course was unremarkable.
Patient 4
A 13-year-old, 28.7-kg boy with mental retardation and cerebral palsy presented with cardiovascular collapse and septic shock. On arrival, the patient's blood pressure was 40 to 50 mmHg by palpation with no peripheral pulses. Initial cardiovascular resuscitation included approximately 110 mL/kg of isotonic fluids and inotropic support with dopamine at 10 mcg/kg/min and epinephrine at 0.1 mcg/kg/min. Respiratory support was provided by noninvasive ventilation (mask BiPaP or bilevel positive airway pressure). Blood cultures were positive for group A β-hemolytic streptococci. Fortyeight hours after admission, the patient's cardiovascular function had stabilized on dopamine at 10 mcg/kg/min and epinephrine at 0.1 mcg/kg/min. Peripheral edema was present, and the extremities were cool with decreased peripheral pulses and capillary refill. Urine output was 0.7 mL/kg/h, with a CVP of 12-14 mmHg. Dobutamine was started at 2.5 mcg/kg/min and increased to 10 mcg/kg/min. The patient's heart rate increased from a baseline of 120 beats/min to 160 beats/min, and the hands and feet remained cool with decreased capillary refill. The blood pressure was 90-100/50-70 mmHg. Nesiritide was started at 0.01 mcg/kg/min. Over the next 4 hours, the patient was weaned from dobutamine, and the nesiritide increased to 0.02 mcg/kg/min. The nesiritide was increased since the extremities were still cool, although improved from baseline. No significant change was noted in the blood pressure and CVP. Heart rate returned to its baseline of 110 to 120 beats/min. After 6 to 8 hours, the hands and feet were warm to the touch, with improved capillary refill. Nesiritide was continued for 48 hours. During this time, the patient was weaned from dopamine, which was then discontinued. Urine output increased from 0.9 mL/kg/h to 1.7 mL/kg/h. The remainder of the patient's hospital course was unremarkable.
Patient 5
A 2-month-old, 4.2-kg infant was admitted to the PICU following mitral valve replacement (mechanical valve). Preoperative cardiac catheterization demonstrated pulmonary artery pressures that were three-quarters systemic. The immediate postoperative course was tenuous with the use of inhaled nitric oxide for pulmonary hypertension and multiple vasoactive agents for cardiovascular support. Ten days after the surgical procedure, the infant's cardiovascular status had improved. The only vasoactive agents were dopamine at 12 mcg/kg/min and milrinone at 0.3 mcg/kg/min. Despite this, maintenance of urine output required a continuous infusion of furosemide/chlorothiazide (0.15 mg and 0.75 mg/kg/h), and the patient's extremities were cool. Nesiritide was started at 0.01 mcg/kg/h, increased to 0.02 mcg/kg/min, and then to 0.03 mcg/kg/h over the next 24 hours to maximize the improvement of urine output and peripheral perfusion. After 24 hours of nesiritide, the diuretic infusion was discontinued, and urine output remained stable with the use of twice-daily doses of butemanide (0.2 mg). Venous oxygen saturation increased (52% to 61%), and the extremities had become warm. The nesiritide infusion was continued for 7 to 8 days.
Discussion
BNP is one of a family of natriuretic peptides that bind to specific receptors located in the kidneys, heart, vascular endothelium, vascular smooth muscle, adrenal glands, and central nervous system [4, 5] . Nesiritide mimics the effects of endogenous BNP through its effect on A-type natriuretic peptide receptors located on the surface of vascular smooth muscle and endothelial cells [4, 5] . The A-type natriuretic peptide receptor is part of the guanylate cyclase family of membrane receptors. Binding of nesiritide to the receptor increases the intracellular levels of cGMP, which then acts as a secondary messenger to mediate arterial and venous vasodilation [4, 5] . The vasodilatory effects of nesiritide are evident from decreases in the pulmonary capillary wedge pressure, pulmonary artery pressure, right atrial pressure, and systemic vascular resistance. Nesiritide has no direct inotropic effect on the heart [2] , which may be beneficial due to the potential association of chronic oral inotropic agents with increased mortality in adult patients with CHF [6, 7] . No increased heart rate or proarrhythmic effects have been reported with nesiritide use in adults with CHF [2, 8, 9] .
In addition to its cardiovascular effects, BNP acts on the renal tubules to inhibit renin-aldosterone secretion, increase urinary sodium excretion, and increase urinary flow rate [3, 10, 11] . While the direct natriuretic and diuretic effects of nesiritide are modest, the improved hemodynamic state with increased peripheral perfusion and improved cardiac output leads to an enhanced diuresis beyond the intrinsic properties of the drug. Adult dosing regimens include an intravenous bolus of 2 mcg/kg, with an infusion of 0.01 to 0.03 mcg/kg/min for maintenance [1, 2] . In adults, the half-life of nesiritide is 18 to 20 minutes, and its cardiovascular effects dissipate within 2 to 4 hours following discontinuation of an infusion. Nesiritide is cleared by receptors on cell surfaces with endocytosis and lysosomal degradation, as well as proteolysis by circulating neutral endopeptidase [4, 5] .
The Vasodilation in the Management of Acute CHF (VMAC) trial examined the benefit of the addition of nesiritide versus nitroglycerin to standard therapy for adult patients with decompensated CHF [2] . VMAC was a randomized, double-blind trial consisting of 489 patients admitted to the hospital with decompensated CHF and dyspnea at rest. For each patient, the choice of whether to use a pulmonary artery catheter was made based on clinical judgment prior to randomization for the study. Patients with and without pulmonary artery catheters were randomized to receive nesiritide, intravenous nitroglycerin (titrated), or placebo added to standard therapeutic medication regimens for 3 or 24 hours [2] . Results from the VMAC study demonstrate the potential cardiovascular advantages of nesiritide versus nitroglycerin in acute, decompensated CHF in adults. When evaluating the changes from baseline, there was a decrease in systemic vascular resistance, pulmonary vascular resistance, pulmonary capillary wedge pressure, and right atrial pressures following treatment with nesiritide. After 1 hour of therapy, mean systemic vascular resistance decreased by 236 dynes/s per cm-5 with nesiritide compared to a 8 dynes/s per cm-5 decrease with placebo and 136 dynes/s per cm-5 with nitroglycerin (P < .05). Mean pulmonary vascular resistance was significantly decreased following 3 hours of treatment with nesiritide (-21 dynes/s per cm-5 ) compared to placebo (+21 dynes/s per cm-5 ) (P < .05). Mean right atrial pressure was decreased with nesiritide treatment at 1 hour (-2.6 mmHg) and 3 hours (-3.1 mmHg) when compared to the change with placebo at 1 hour (-0.2 mmHg) and 3 hours (0 mmHg). The change in mean pulmonary capillary wedge pressure in patients treated with nesiritide was -5.8 mmHg at 3 hours versus -3.8 mmHg in the nitroglycerin group (P = .03) and -2 mmHg in the placebo group (P < .001). At 24 hours, the decrease in mean pulmonary capillary wedge pressure was -8.2 mmHg with nesiritide administration compared to a decrease of -6.3 mmHg with nitroglycerin administration (P < .05). Patients receiving nesiritide reported improvement of dyspnea compared to the placebo group; however, no difference was noted between the nesiritide and nitroglycerin treatment groups. The authors concluded that nesiritide is more effective in improving hemodynamic function and symptoms than are intravenous nitroglycerin or placebo in adults with acutely decompensated CHF [2] .
In a multicenter trial, Silver et al compared the effects of nesiritide versus dobutamine administration in 305 adult patients with symptomatic decompensated CHF who required hospitalization [6] . Adult patients who required intravenous therapy and hospitalization were randomized to receive either standard care (intravenous dobutamine, milrinone, nitroglycerin, or nitroprusside), nesiritide bolus of 0.3 mcg/kg followed by 0.015 mcg/kg/min, or nesiritide 0.6 mcg/kg intravenous bolus followed by 0.03 mcg/kg/min infusion. For the standard care group, a second intravenous agent (not nesiritide) could be added. The 0.015 mcg/kg/min nesiritide treatment group had a decrease in blood pressure of 14.1 mmHg ± 18.96 mmHg, while the 0.03 mcg/kg/min nesiritide group had a decrease of 14.8 mmHg ± 21.30 mmHg. The blood pressure decrease in the dobutamine treatment group was 3.5 mmHg ± 17.30 mmHg (P < .05). After 24 hours of treatment, heart rate in the 3 treatment groups remained the same, and there was no significant change in diastolic blood pressure.
The investigators examined health care costs by evaluating length of hospital stay, readmission rate, and short-term morbidity of nesiritide versus dobutamine. There was no difference in the length of hospital stay between patients receiving dobutamine versus nesiritide. Patients receiving nesiritide had a shorter duration of use of intravenous therapy compared to those receiving dobutamine: 25 hours shorter duration for patients receiving nesiritide 0.015 mcg/kg/minute and 39 hours shorter duration for patients receiving nesiritide 0.030 mcg/kg/min when compared to patients treated with dobutamine (P < .05). Sixty-nine percent fewer adult patients receiving nesiritide were readmitted for CHF within 21 days of initial therapy compared to the group that received dobutamine. The 6-month mortality in the dobutamine treatment group was 31%, compared to 18% in the 0.015 mcg/kg/min nesiritide treatment group and 24% in the 0.03 mcg/kg/min nesiritide treatment group. The investigators concluded that using nesiritide as a therapy for decompensated CHF may decrease health care costs and lower mortality when compared to the use of dobutamine.
Our cohort of 5 patients provides preliminary experience regarding the use of nesiritide in the pediatric population ( Table 1 ). The cohort included a diverse patient population including 2 patients who were status postcardiothoracic surgery, 2 with acute respiratory distress syndrome (ARDS), and 1 in the recovery phase from septic shock. Although no direct measurement of cardiac output was feasible as none of the patients had an indwelling pulmonary artery catheter, other indicators of increased cardiac output were noted in all of the patients. These included improved peripheral perfusion with warming of the extremities and improvement of peripheral pulses (n = 5), increased venous saturation in the patients in whom this was measured (n = 2), and maintenance of or increased urine output despite discontinuation or decreasing diuretic dose (n = 5). In 3 of the patients, nesiritide was started as the primary agent to provide a decrease in systemic vascular resistance and augment cardiac output, while in the other 2 patients, nesiritide was added when tachycardia occurred with dobutamine or when milrinone failed to provide the desired effect. In our fourth patient, nesiritide was effective while avoiding the tachycardia that occurred with dobutamine. In our fifth patient, we noted improvement in peripheral perfusion and mixed venous oxygen saturation when switching from milrinone at 0.3 mcg/kg/min to nesiritide.
Two of the patients who received nesiritide had ARDS, requiring HFOV to maintain oxygenation. The constant mean airway pressure of HFOV combined with ARDS can have several deleterious effects on cardiovascular function including decreased venous return and increased pulmonary vascular resistance (PVR). Elevated PVR can compromise right ventricular performance, thereby decreasing left-sided filling. The cumulative effect of these physiological responses can be a decrease in cardiac output with a compensatory increase in systemic vascular resistance. This may result in decreased end-organ perfusion and a decrease in urine output (0.5 ml/kg/h in patient 1 prior to instituting nesiritide) or the need for diuretic therapy that can cause a further decrease in preload, resulting in prerenal azotemia. Given nesiritide's beneficial effects on systemic vascular resistance, renal blood flow, and sodium/water homeostasis, we felt that it would be a useful agent in this setting. In addition, the VMAC study has demonstrated a decrease in PVR with nesiritide therapy [2] . Two of the patients treated with nesiritide were status postcardiothoracic surgery, including a 3month-old following aortic coarctation repair. Following surgery, blood pressure increased (110-120/70-80 mmHg) with a decrease in urine output (1.3 ml/kg/h). Treatment of hypertension in newborns and infants can be difficult due to potential adverse effects seen with the currently available treatment options. Nitroprusside therapy can be problematic because of the potential to cause excessive hypotension or toxicity. Calcium channel blockers have resulted in cardiovascular collapse and are generally not recommended in infants younger than 6 to 12 months of age. Although we have previously used nicardipine in this setting [12] , with the recent introduction of nesiritide for clinical use, we felt that it would be a potentially safer and more appropriate agent in this clinical scenario. Nesiritide was started at an infusion rate of 0.01 mcg/kg/min and subsequently increased to 0.02 mcg/kg/min to achieve blood pressure control. Nesiritide led to a reduction of blood pressure of 70-90/40-50 mmHg and an increase of urine output (2.6 mL/kg/h). The 1 episode of hypertension associated with agitation was well controlled with analgesic medication. Transition from nesiritide as acute antihypertensive therapy to oral maintenance therapy proceeded without difficulty. Although an isolated case, success in this patient suggests a potential additional roll for nesiritide in the newborn population with hypertension. This option is especially important considering the potential adverse effects of other antihypertensive agents.
The fourth patient also had postcardiothoracic surgery status (mitral valve replacement). Despite milrinone in doses up to 0.3 mcg/kg/min, the patient had poor peripheral perfusion with cool extremities. Urine output was dependent on the frequent use of diuretics. With the switch from milrinone to nesiritide, we noted a stable urine output with a decreased use of diuretic agents (switching from a continuous lasix/diuril infusion to twicedaily doses of bumetanide), improved peripheral perfusion with warm hands and feet, and an increase in the mixed venous oxygen saturation. Our final patient was a 13-year-old who presented with cardiovascular collapse and septic shock. Following stabilization on dopamine and epinephrine, there was evidence of poor peripheral perfusion including cool extremities, poor capillary refill, and low urine output (0.9 mL/kg/h). Dobutamine therapy resulted in tachycardia without improvement in clinical signs of peripheral perfusion. Nesiritide was started at 0.02 mcg/kg/min, and the dobutamine infusion was discontinued. The administration of nesiritide and discontinuation of dobutamine resulted in a return of heart rate to predobutamine levels and improved peripheral perfusion (improved capillary refill time and increase in peripheral temperature). In addition, urine output doubled to 1.7 ml/kg/h. These findings are consistent with reports from trials in adults as the administration of nesiritide has been not associated with the proarrhythmogenic effects and tachycardia that can be seen with dobutamine [8, 9] .
Dosing for our pediatric patients was extrapolated from the adult literature. We currently use a concentration of 6 mcg/mL in normal saline. No bolus doses were given at the initiation of therapy due to the lack of dosing information in children and the theoretical risk of hypotension with a loading dose. As the clinical experience increases in pediatric patients, it may be appropriate to use a loading dose prior to initiation of the infusion. With the initiation of a continuous infusion or changes in the dosing regimen, given its half-life of 18 to 20 minutes, manifestation of its full clinical effects should be evident in 90 to 100 minutes (5 half-lives). We would suggest the initiation of the infusion at 0.01 mcg/kg/min with increases every 2 to 3 hours as needed in increments of 0.01 mcg/kg/min up to 0.03 to 0.05 mcg/kg/min. The nesiritide dose is increased as needed to optimize its effects on peripheral perfusion, urine output, blood pressure, or mixed venous oxygen saturation.
No adverse clinical effects were noted with nesiritide in our cohort of patients. As has been reported in the adult literature, we noted no increase in heart rate and no arrhythmogenic effects. Also of interest, in the 2 patients with closed head injury who had invasive intracranial pressure (ICP) monitoring, we noted no change in ICP readings with nesiritide administration. As its predominant effect is vasodilatation, it is conceivable that, like other agents with vasodilatory properties, it could result in cerebral vasodilatation and increases in ICP. Likewise, in the 2 patients with ARDS, we saw no evidence of interference with hypoxic pulmonary vasoconstriction and worsening of oxygenation, another effect that has been observed when using nonspecific vasodilators in this setting.
In summary, we present preliminary clinical experience with nesiritide in pediatric-aged patients. In our cohort of patients, nesiritide therapy resulted in improved peripheral perfusion, increased mixed venous oxygen saturation in 2 of the patients in which it was measured, and either increased urine output or maintenance of urine output with decreased diuretic use. Avoidance of diuretic use may be important clinically due to evidence of increased mortality in patients with left ventricular dysfunction and patients with renal failure [13, 14] . In reviewing these case reports, other questions and issues surfaced. As clinical work with endogenous BNP continues to increase, it may be appropriate to determine whether baseline BNP levels can help to identify those patients who will benefit most from nesiritide therapy. There is a definite need for pharmacokinetic studies to provide dosing guidelines (bolus and infusion) for all age groups of the pediatric population. In adults, nesiritide has been shown to lower PVR. Given the current cost of nitric oxide, nesiritide's role in this setting is particularly intriguing. Although nesiritide is more costly than other vasoactive agents (acquisition costs of approximately $380 for 1.5-mg vial), once reconstituted, it remains stable for at least 48 hours, which allows the use of 1 vial for 48 hours in smaller patients rather than mixing new infusions every day. Given the expected limitations of venous access in many PICU patients, we noted that there were no physical incompatibilities when nesiritide was administered through the same port of a central venous catheter with other solutions or medications including epinephrine, dopamine, dobutamine, amiodarone, heparin, fentanyl, midazolam, lidocaine, vasopressin, and parenteral nutrition solutions with glucose concentrations up to 25%. In addition, given its predominant vasodilatory effects, nesiritide can also be administered via a peripheral intravenous site with limited concerns for tissue damage should infiltration occur.
